Nancy is the Chief Executive Officer of Recludix and has an established track record in all phases of drug development. Nancy is a 15-year veteran of Seagen, formerly Seattle Genetics. Most recently, she was the Executive Vice President of Corporate Strategy, where she had the broad remit of corporate strategy and planning, strategic alliances and partnerships, investor relations, corporate communications and information technologies. She previously served as Executive Vice President of Late Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine. During her tenure at Seagen, Nancy played a central role in the development and regulatory approval of ADCETRIS for lymphoma, PADCEV for bladder cancer, TUKYSA for breast cancer, TIVDAK for cervical cancer, and several other pipeline compounds. Prior to transitioning to the pharmaceutical industry, Dr. Whiting practiced as a Clinical Oncology Pharmacist at the Seattle Cancer Care Alliance. Dr. Whiting completed her undergraduate training at the University of British Columbia and received her Pharm.D. from the University of Washington. She also completed a residency in clinical pharmacy practice at Vancouver General Hospital. Dr. Whiting is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the European Society of Medical Oncology. She serves on the Board of Directors of Caribou BioSciences and also Boundless BioSciences.
« Go Back